• PDF / 169,508 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 37 Downloads / 165 Views

DOWNLOAD

REPORT

---

1 S

Anticoagulants/ibrutinib Haematomas with localisation on the neck and face, haemorrhages in the anterior chamber of the eye and macrohematuria: 3 case reports

A study of 224 patients with chronic lymphocytic leukemia (CLL) described three patients, who developed haematomas with localisation on the neck and face (1 patient), haemorrhages in the anterior chamber of the eye (1 patient) and macrohematuria (1 patient) during treatment with ibrutinib and unspecified anticoagulants [not all routes and dosages stated; durations of treatments to reactions onsets and outcomes not stated]. The patients, who had CLL, started receiving ibrutinib 420 mg/day. Thereafter, the patients experienced atrial fibrillation [aetiology not stated]. Thus, the patients started receiving anticoagulant therapy with unspecified novel oral anticoagulants. Thereafter, the patients developed large, recurring haematomas with localisation on the neck and face (n=1), haemorrhages in the anterior chamber of the eye (n=1) and recurrent macrohematuria (n=1), which were attributed to ibrutinib and unspecified anticoagulants. The patient, who had developed recurrent macrohaematuria, discontinued anticoagulant therapy, while the remaining two patients were transferred to the minimum dose of apixaban. Emelina E, et al. Experience with the use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation and a high risk of hemorrhagic complications. Europace 22 (Suppl. 1): i206 abstr. P471, Jun 2020. Available from: URL: http://doi.org/10.1093/europace/euaa162.310 [abstract]

0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

803507556

Reactions 17 Oct 2020 No. 1826